Screening predictive targets for efficacy evaluation of chemotherapy and targeted drug therapy in advanced colorectal cancer from the view of gut flora and microbial metabolites

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022432

Enrollment

Unknown

Registered

2019-04-11

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

The effective group:Targeted therapy

The less effective group:Targeted therapy

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis for advanced colorectal cancer patients; 2. Patients have not underwent these treatments including surgery, chemotherapy, radiotherapy; 3. Patients who have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who combined with other malignant tumors; 2. Patients who combined with serious heart and lung disease; 3. The patient had a history of using antibiotics, hormones or intestinal flora preparations 3 months before admission; 4. Patients who combined with crohn's disease, ulcerative colitis and other intestinal diseases.

Design outcomes

Primary

Measure	Time frame
Flora;metabolites;	—

Countries

China

Contacts

Public ContactHan Shuwen

Huzhou Central Hospital

Shuwenhan985@163.com+86 05722555750

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026